Pamela J. Cheshire

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

Peter J. Houghton, Pamela J. Cheshire, James D. Hallman et al. · Cancer Chemotherapy and Pharmacology · 1995 · 406 citations

Human Tumors, Oncology, Medicine +9

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

Lorina Dudkin, Michael B. Dilling, Pamela J. Cheshire et al. · PubMed · 2001 · 232 citations

Chemoprevention Strategy, Cancer Biology, Tumor Biology +19

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

Peter J. Houghton, Pamela J. Cheshire, Leann Myers et al. · Cancer Chemotherapy and Pharmacology · 1992 · 229 citations

Medicine, Childhood Solid Tumors, Pharmacology +6

Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

Clinton F. Stewart, Markos Leggas, John D. Schuetz et al. · Cancer Research · 2004 · 199 citations

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

Peter J. Houghton, Pamela J. Cheshire, James C. Hallman et al. · PubMed · 1993 · 161 citations

Tumor Biology, Human Tumor Xenografts, Medicine +14